Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04352439 · ClinicalTrials.gov registry record · Phase 4
Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT04352439 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 19 participants.
The verdict
NCT04352439, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a pilot study to determine the safety and efficacy of low dose aspirin for the prevention of venous thromboembolism among women with advanced ovarian cancer receiving neoadjuvant chemotherapy.
Interventions
- DRUG Aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-08-08 |
| Est. Completion | 2022-03-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04352439
The ClinicalTrials.gov registry entry for NCT04352439 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aspirin is the first listed.
NCT04352439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04352439 about?
NCT04352439 is a clinical study titled "Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy". This is a pilot study to determine the safety and efficacy of low dose aspirin for the prevention of venous thromboembolism among women with advanced ovarian cancer receiving neoadjuvant chemotherapy.
What is the current status of trial NCT04352439?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2020-08-08. Estimated completion is 2022-03-02.
What interventions are being tested in trial NCT04352439?
The interventions under investigation include: Aspirin (DRUG).
Who is sponsoring clinical trial NCT04352439?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.